BTIG Maintains Sell on Talis Biomedical, Raises Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Mark Massaro maintains a 'Sell' rating on Talis Biomedical (NASDAQ:TLIS) and raises the price target from $0.35 to $5.
August 16, 2023 | 2:27 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
BTIG analyst Mark Massaro maintains a 'Sell' rating on Talis Biomedical and raises the price target from $0.35 to $5.
The 'Sell' rating maintained by BTIG indicates a negative outlook for Talis Biomedical. However, the increase in price target from $0.35 to $5 suggests that the analyst sees some potential for the stock's price to rise, albeit not enough to change the overall negative rating. This could lead to short-term volatility in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100